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Abstract: The recommendations on the intake of long chain omega-3 polyunsaturated fatty
acids (n-3 LC-PUFA) vary from eating oily fish (“once to twice per week”) to consuming
specified daily amounts of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
(“250–500 mg per day”). It is not known if there is a difference in the uptake/bioavailability
between regular daily consumption of supplementsvs. consuming fish once or twice per
week. In this study, the bioavailability of a daily dose of n-3 LC-PUFA (Constant treatment),
representing supplements, vs. a large weekly dose of n-3 LC-PUFA (Spike treatment),
representing consuming once or twice per week, was assessed. Six-week old healthy male
Sprague-Dawley rats were fed either a Constant treatment, a Spike treatment or Control
treatment (no n-3 LC-PUFA), for six weeks. The whole body, tissues and faeces were
analysed for fatty acid content. The results showed that the major metabolic fate of
the n-3 LC-PUFA (EPA+docosapentaenoic acid (DPA) + DHA) was towards catabolism
(β-oxidation) accounting for over 70% of total dietary intake, whereas deposition accounted
less than 25% of total dietary intake. It was found that significantly more n-3 LC-PUFA
were β-oxidised when originating from the Constant treatment (84% of dose), compared
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with the Spike treatment (75% of dose). Conversely, it was found that significantly more
n-3 LC-PUFA were deposited when originating from the Spike treatment (23% of dose),
than from the Constant treatment (15% of dose). These unexpected findings show that a
large dose of n-3 LC-PUFA once per week is more effective in increasing whole body n-3
LC-PUFA content in rats compared with a smaller dose delivered daily.
Keywords: bioavailability; EPA; DHA; DPA; metabolic fate; tissue deposition;
frequency of intake
1. Introduction
A vast body of literature exists on the effect of long chain omega-3 polyunsaturated fatty acids
(n-3 LC-PUFA) in the areas of infant development [1], cardiovascular disease, platelet aggregation [2],
cancer [3], dementia, Alzheimer’s disease, depression [4,5], and inflammation [6,7].
Recommendations for eicosapentaenoic acid (EPA; 20:5n-3) plus docosahexaenoic acid (DHA;
22:6n-3) intake have been put forth by several organizations globally, with ranges from 250 mg to
500 mg per day for adults with an additional 200 mg of DHA per day for pregnant and lactating
women [8]. The recommendation for patients with coronary heart disease generally is 1 g EPA plus
DHA per day, and for patients with high triglycerides the recommendations range from 1.2 to 4 g EPA
plus DHA per day [8]. Some organisations, including the American Heart Association and Australian
National Health and Medical Research Council, recommend foods (oily fish) once to twice per week [9],
whereas others like the National Heart Foundation of Australia deal with nutrients daily based on daily
intake (250–500 mg per day of EPA plus DHA) [10]. Accordingly, despite the actual quantity of
recommended intake, it appears to be important to understand what feeding strategy, such as a constant
daily dose or large doses fewer times per week, is more efficient to fulfil dietary requirements of EPA
and DHA.
There are two human studies which have compared a constant daily dose of n-3 LC-PUFA vs. twice
weekly doses of n-3 LC-PUFA [11,12]. Harris et al. [11] compared the bioavailability of EPA and
DHA from twice weekly consumption of oily fish (3.40 g/week EPA + DHA) with daily fish-oil capsule
supplementation (3.37 g/week EPA + DHA) in a 16 week study in 23 women; they found that there
were no treatment differences in the EPA and DHA content of red blood cell membranes or plasma
phospholipids. Browning et al. [12] compared the bioavailability of EPA and DHA from fish oil capsules
(twice per week) with daily fish oil consumption. Male and female participants (n = 65) were given
capsules (containing 6.54 g of EPA and DHA per week) either twice weekly or daily for one year. They
found that there was no difference between treatments in the plasma phosphatidylcholine level of EPA
and DHA, but that there were significantly higher levels of EPA and DHA in platelets and higher levels
of EPA in mononuclear cells. Both studies used blood (plasma or red cell) levels of n-3 LC-PUFA as a
proxy for bioavailability, which as discussed previously has significant limitations [13].
The aim of the present study was to compare the bioavailability and efficiency (as metabolic fate)
of the same amount of dietary n-3 LC-PUFA administered either as a constant daily dose (Constant
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treatment)vs. a single weekly dose (Spike treatment). It was hypothesized that a single weekly dose of
n-3 LC-PUFA would not be as bioavailable as a continuous daily dose of n-3 LC-PUFA.
2. Materials and Methods
2.1. Diet and Study Design
This study was performed following the Australian code for the care and use of animals for scientific
purposes and approved by the Deakin University Animal Welfare Committee (G29-2012).
Forty eight 6-week old, sexually mature, healthy male Sprague-Dawley rats were purchased from
Animal Resources Centre, Western Australia. Rats were housed in pairs (2 rats per cage; 24 cages in
total) and acclimatised for a week on ad libitum normal chow diet. The 24 cages of rats were randomly
divided into four groups of six cages each. One group (six cages) was sacrificed via CO2 overdose at day
0 for the baseline data. The other three groups (six cages each) were randomly allocated to three different
dietary treatments (feeding regimes), named “Control”, “Constant” and “Spike”. To achieve these three
different dietary treatments, three specifically formulated diets were designed and manufactured to be
iso-proteic, iso-lipidic (10% fat by weight, Speciality Feeds, Western Australia), and named: “No n-3
LC-PUFA diet”, “Constant diet” and “Spike diet”. The “No n-3 LC-PUFA diet” was formulated to
contain no fish oil, and thus no n-3 LC-PUFA; the “Constant diet” was formulated to contain 0.7% of
fish oil (mixed fish oils), and the “Spike diet” was formulated to contain a 4.9% of the same fish oil
(a 7-fold higher level of n-3 LC-PUFA compared with the “Constant diet”) (Table 1). Based on these
three experimental diets, three different dietary treatments (feeding regimes) Control, Constant and Spike
were implemented. In the “Control” treatment rats were fed only with the “No n-3 LC-PUFA diet”, in
the “Constant” treatment rats were fed only with the “Constant diet”, and in the “Spike” treatment the
rats were fed 6 days/week with the “No n-3 LC-PUFA diet”, and one day per week with the “Spike diet”.
To ensure equal intake amongst dietary treatments during the experimentation, animals were fed to fixed
predetermined ration, which was adjusted weekly relative to body weight, for 6 weeks. To determine
the appropriate food ration, a preliminary short trial was implemented over a three-week period, where
15 rats of similar size were fed ad-libitum and total feed consumption was recorded. Then, using a
regression equation comparing body weight (BW), the daily ration in grams, was estimated as:
Ration p% BWq “ ´0.0283BW ` 16.6 (1)
Therefore, the experimental design for the rats in the Constant and Spike treatments was to consume
exactly the same amount of fish oil (and therefore n-3 LC-PUFA) over a 7-day period, in order to
establish if there was a difference in whole body bioavailability between these two feeding strategies
(daily vs. weekly).
Throughout the 6-week trial period, the rats were weighed (twice per week), and faeces were collected
every day during the last two weeks. After the 6 weeks, the rats were humanely sacrificed via CO2
overdose. Six rats from each treatment (one per cage) were used for analysis of whole body lipids and
the other six rats (one per cage) were used for the analysis of the individual tissue lipid contents. The
collected faeces, whole body and tissues (liver, heart, white gastrocnemius muscle and perirenal adipose
tissue) were analysed for fatty acid content.
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Table 1. Experimental diet formulation, proximate composition and selected fatty
acid concentrations.
Composition No n-3 LC-PUFA Diet Constant Diet Spike Diet
(a) Diet Formulation and Proximate Composition *
Diet formulation (%)
Sucrose 10.00 10.00 10.00
Casein (acid) 20.00 20.00 20.00
Starch 37.44 37.44 37.44
Dextrinised starch 13.20 13.20 13.20
Safflower oil 0.05 0.13 0.64
Palm oil 9.88 9.11 4.45
Linseed oil 0.07 0.06 0.01
Fish oil ** 0.00 0.70 4.90
Proximate Composition (mg/g of Diet)
Protein 194.00 194.00 194.00
Fibre 84.00 84.00 84.00
Fat 100.00 100.00 100.00
(b) Fatty Acid Concentration of the Diet After Formulation(mg/g of Diet)
16:0 43.00 38.50 26.40
18:0 4.00 3.81 3.10
18:1n-9 28.20 26.90 18.21
18:2n-6 7.71 7.82 7.20
20:4n-6 0.00 0.05 0.27
18:3n-3 0.50 0.50 0.30
18:4n-3 0.00 0.10 0.71
20:5n-3 (EPA) 0.00 0.90 4.50
22:5n-3 (DPA) 0.00 0.12 0.51
22:6n-3 (DHA) 0.00 0.60 2.92
EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid), DPA (docosapentaenoic acid); * Diet formulation
and proximate composition reported from data from the feed company; ** Fish oil was a mixture of fish oils
used in diet manufacture. The mixture was made at the diet formulators premises before use; n-3 LC-PUFA,
long chain omega-3 polyunsaturated fatty acids.
2.2. Lipid Analysis
The whole body, tissues and faeces samples were homogenized, and the lipids extracted by
dichloromethane:methanol (2:1), a modification of the method described by Folch et al. [14]. Fatty
acids derived from the lipids were methylated using an acid-catalysed trans-methylation [15]. In brief,
an aliquot of fatty acids derived from the lipids plus a known amount of internal standard of tricosanoic
acid (C23:0 >99%; Nu-Chek Prep Inc., Elysian, MN, USA) were reacted with acetyl chloride/methanol
to form fatty acid methyl esters (FAME). The resulting FAME were separated, identified and quantified
using an Agilent Technologies 7890A gas chromatography system (Agilent Technologies; Santa Clara,
CA, USA) equipped with a BPX70 capillary column (120 m, 0.25 mm internal diameter, 0.25 µm film
thickness; SGE Analytical Science, Melbourne, Australia), an Agilent Technologies 7693 autosampler,
a split injection system and a flame ionisation detector using established protocols [16].
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2.3. Lipid and Fatty Acid Apparent Digestibility
Apparent digestibility of total lipid was measured according to Tou et al. [17] as ((lipid intake´ faecal
lipid)/(lipid intake))ˆ 100. Similarly, apparent digestibility of individual fatty acids was measured using
the formula ((fatty acid intake ´ fatty acid excretion in faeces)/(fatty acid intake)) ˆ 100. Lipid intake
was determined as diet consumed per week ˆ % lipid in the diet. Likewise, fatty acid intake was
determined as diet consumed per week ˆ % fatty acid in the diet. Faecal lipid and fatty acids were
determined as total faeces excreted per week (pooled 7 days faecal samples) ˆ% lipid and % fatty acids
in the faeces respectively.
2.4. Whole Body Fatty Acid Balance Method
The fatty acid metabolism of rats was determined using the Whole Body Fatty Acid Balance Method,
as conceived and described by Turchini et al. [18], with subsequent developments [19]. Briefly, the
first step of the method required that the net appearance or disappearance of each individual fatty acid
be determined by the difference between total fatty acid accumulation (=final fatty acid content-initial
fatty acid content) and the net fatty acid intake (=total fatty acid intake-fatty acid excretion in faeces),
as initially proposed by Cunnane’s group [20–22]. Then, after the transformation of data from gram
per animal per the duration of the trial to mol of fatty acid per gram of body weight per day,
the subsequent second step involved a series of backwards computations along all the known fatty
acid bioconversion pathways, therefore the fate of each individual fatty acid towards bioconversion,
β-oxidation or deposition was determined and quantified. Eventually, data relative to apparent in vivo
enzyme activity could be reported as nmol of enzyme’s product per gram of body weight per day, and
the in vivo metabolic fate (absorption, β-oxidation, bioconversion and deposition) of each dietary fatty
acid could be reported as a % relative to the dietary intake.
2.5. Statistical Analysis
All data are reported as mean ˘ SD (standard deviation) of the six cages per treatment (n = 6,
N = 18). The experimental unit was the cage (with two rats per cage). Significant differences between
experimental treatments were tested using one-way analysis of variance (ANOVA), assessing the effects
of diets, with an exception of using t-test for the n-3 LC-PUFA apparent digestibility (as only two
treatments were considered). Paired tests were performed with Tukey’s test. Statistical significance
was considered for p < 0.05. Data analysis was performed with Minitab Statistical Software (Version 16;
Minitab Inc., State College, PA, USA).
3. Results
3.1. Feed and n-3 LC-PUFA Intake
As described in the methods, rats were fed to fixed predetermined ration, which was adjusted weekly
relative to body weight, for 6 weeks. Rats in the Control and Spike treatments consumed all the diet
provided each week; however, rats in the Constant treatment left some food uneaten, especially in week
three, and this was recorded and accounted for (Table 2).
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Table 2. Actual feed intake over the six weeks of the experiment in the three treatments.
Total Diet Intake (g/rat/6 weeks) Control Constant Spike
No n-3 LC-PUFA diet 938 ˘ 32 - -
Constant diet - 931 ˘ 44 804 ˘ 25
Spike diet - - 134 ˘ 11
Values are expressed as the mean ˘ SD of 6 cages per group; n-3 LC-PUFA, long chain omega-3
polyunsaturated fatty acids.
An important result that has to be noted and carefully considered was the fatty acid concentration of
the experimental diets. Despite the prescribed formulation with 0.7% of fish oil in “Constant diet”, and
4.9% fish oil in “Spike diet” (and fish oil being the only source of dietary n-3 LC-PUFA), the resulting
manufactured diets had slightly different total amounts of n-3 LC-PUFA than expected (Table 1b).
The “Constant diet” recorded EPA + DHA + DPA = 1.6 mg/g of diet, and the “Spike diet” recorded
EPA + DHA + DPA = 8.0 mg/g of diet (a 5-fold difference, rather than the expected 7-fold difference).
3.2. n-3 Fatty Acid Apparent Digestibility
The effect of Constant and Spike treatments on apparent digestibility is shown in Table 3. There
were small, but significant differences observed in EPA and DHA apparent digestibility between these
two treatments, which was higher in the Constant, compared with the Spike treatment. However, DPA
apparent digestibility was similar between Constant and Spike treatments.
Table 3. The effect of Constant and Spike treatments on the long chain omega-3
polyunsaturated fatty acids (n-3 LC-PUFA) apparent digestibility.
Constant Spike p-Value
20:5n-3 (EPA) 99.4 ˘ 0.0 99.0 ˘ 0.9 0.021
22:5n-3 (DPA) 96.9 ˘ 1.0 96.5 ˘ 0.4 0.753
22:6n-3 (DHA) 98.8 ˘ 0.5 98.2 ˘ 0.2 0.042
Values are expressed as the mean ˘ SD of 6 cages per group; Control treatment not reported as no
n-3 LC-PUFAwas provided by the diet; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA,
docosahexaenoic acid.
3.3. Growth and Biometrical Parameters
There was no significant difference (p = 0.856) in the body weight of rats between the three
experimental treatments during the six weeks of the experiment. The average body weights (˘SD)
of animals in the Control, Constant and Spike treatments were 412 ˘ 6 g, 413 ˘ 6 g, and 409 ˘ 11 g
respectively, at the end of the experiment (Table 4).
In regard to the tissue weight, there was no significant difference in the tissue weight of rats between
the three dietary treatments at the end of the experiment. In addition, the Hepatosomatic Index and
Perirenal adipose-somatic index showed no significant difference in the Constant and Spike treatment
compared with the Control (Table 4).
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Table 4. The effect of Constant and Spike treatments on rat tissue weight and
biometric parameters.
Weight (g) Control Constant Spike p-Value
Whole body 412.4 ˘ 6.2 412.6 ˘ 6.2 409.3 ˘ 10.8 0.714
Liver 17.9 ˘ 2.5 17.3 ˘ 2.1 17.0 ˘ 0.8 0.914
Heart 1.5 ˘ 0.2 1.5 ˘ 0.1 1.5 ˘ 0.1 0.547
Perirenal adipose 7.6 ˘ 2.9 6.8 ˘ 2.9 8.5 ˘ 1.9 0.225
Muscle 0.8 ˘ 0.1 0.7 ˘ 0.1 0.7 ˘ 0.1 0.856
HSI* 4.3 ˘ 0.6 4.2 ˘ 0.6 4.0 ˘ 0.3 0.432
PASI** 1.8 ˘ 0.7 1.7 ˘ 0.7 2.0 ˘ 0.4 0.543
Control, Constant and Spike treatments provided 0 mg, 9.2 mg and 8 mg per week of EPA + DPA + DHA,
respectively; Values are expressed as the mean ˘ SD of 6 cages per group; * HSI (Hepatosomatic Index, liver
weight/whole body weight ˆ 100); ** PASI (Perirenal adipose-somatic index, Perirenal adipose weight/whole
body weight ˆ 100).
3.4. Lipid Content of Rat Whole Body and Tissues
Whole body and tissue lipid content (mg/g tissue wet weight) of all rats at the conclusion of
the study were significantly higher compared with the baseline data (p < 0.001). There was no
significant difference in the total lipid content of the whole body or tissues between the three dietary
treatments (Table 5).
Table 5. Lipid content of tissues of rats fed the different experimental treatments.
Lipid Content Control Constant Spike p-Value
Whole Body (mg/g Whole Body) 133.7 ˘ 17.1 119.1 ˘ 12.6 111.4 ˘ 28.8 0.199
Tissues (mg/g Tissue)
Liver 53.3 ˘ 16.9 51.6 ˘ 6.4 51.1 ˘ 8.1 0.942
Heart 29.8 ˘ 2.6 28.8 ˘ 0.8 30.7 ˘ 1.4 0.168
Perirenal adipose 831.2 ˘ 89.4 893.0 ˘ 27.4 931.2 ˘ 67.9 0.640
Muscle 19.5 ˘ 3.5 20.0 ˘ 2.8 24.7 ˘ 8.0 0.209
Values are expressed as the mean ˘ SD of 6 cages per group.
3.5. The Fatty Acid Concentration of the Rat Whole Body and Tissues
As shown in Table 6, the whole body fatty acid concentration for rats that received the Constant
treatment was significantly higher for all n-3 LC-PUFA compared with rats on the Spike treatment at the
end of experiment (p < 0.05). In addition, n-6 PUFA concentrations were significantly lower in the Spike
compared with the Constant treatment at the end of the study period (p = 0.003). It should be recalled that
rats in the Spike treatment received a relatively smaller amounts of n-3 LC-PUFA each week compared
with the Constant treatment, because the manufactured diet slightly deviated from expected final fatty
acid concentration.
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Table 6. Selected fatty acid content of whole body (mg/g whole body) and tissues (mg/g
tissue) from rats fed different dietary treatments.
PUFA n-6 PUFA n-3 EPA DPA DHA EPA + DPA + DHA
Whole Body(mg/g Whole Body)
Control 11.23 ˘ 1.50b 0.83 ˘ 0.12a n.d 0.06 ˘ 0.01a 0.30 ˘ 0.08a 0.37 ˘ 0.09a
Constant 10.88 ˘ 1.12b 1.76 ˘ 0.08c 0.16 ˘ 0.02b 0.22 ˘ 0.02c 0.88 ˘ 0.06c 1.26 ˘ 0.08c
Spike 9.30 ˘ 1.38a 1.49 ˘ 0.13b 0.12 ˘ 0.02a 0.19 ˘ 0.02b 0.75 ˘ 0.05b 1.07 ˘ 0.07b
p-Value 0.003 0.001 0.001 0.001 0.001 0.001
Liver (mg/g Liver)
Control 7.1 ˘ 1.7b 1.1 ˘ 0.2a 0.03 ˘ 0.01a 0.05 ˘ 0.01a 0.61 ˘ 0.19a 0.68 ˘ 0.19a
Constant 5.7 ˘ 1.1a 2.2 ˘ 0.3b 0.31 ˘ 0.03b 0.14 ˘ 0.02b 1.47 ˘ 0.32b 1.92 ˘ 0.37b
Spike 7.8 ˘ 1.0b 2.6 ˘ 0.5b 0.28 ˘ 0.08b 0.19 ˘ 0.05c 1.72 ˘ 0.50b 2.20 ˘ 0.56b
p-Value 0.049 0.001 0.001 0.001 0.001 0.001
Heart (mg/g Heart)
Control 6.01 ˘ 0.34b 0.96 ˘ 0.08a 0.02 ˘ 0.01a 0.08 ˘ 0.00a 0.65 ˘ 0.07a 0.74 ˘ 0.07a
Constant 4.70 ˘ 0.32a 2.34 ˘ 0.13b 0.11 ˘ 0.01b 0.25 ˘ 0.03b 1.86 ˘ 0.11b 2.21 ˘ 0.13b
Spike 5.24 ˘ 0.39b 2.27 ˘ 0.23b 0.11 ˘ 0.00b 0.29 ˘ 0.03b 1.73 ˘ 0.21b 2.12 ˘ 0.20b
p-Value 0.001 0.001 0.001 0.001 0.001 0.001
Perirenal Adipose(mg/g Perirenal)
Control 4.6 ˘ 0.7a 0.3 ˘ 0.0a n.d 0.01 ˘ 0.01a 0.01 ˘ 0.00a 0.03 ˘ 0.01a
Constant 7.7 ˘ 2.6a 0.7 ˘ 0.2b 0.06 ˘ 0.02a 0.12 ˘ 0.06b 0.09 ˘ 0.03b 0.28 ˘ 0.09b
Spike 7.1 ˘ 0.6a 0.7 ˘ 0.1b 0.07 ˘ 0.01a 0.16 ˘ 0.03b 0.11 ˘ 0.04b 0.34 ˘ 0.06b
p-Value 0.543 0.001 0.001 0.001 0.001 0.001
Muscle (mg/g Muscle)
Control 3.37 ˘ 0.70b 0.92 ˘ 0.38a 0.08 ˘ 0.05a 0.09 ˘ 0.01a 0.34 ˘ 0.13a 0.51 ˘ 0.19a
Constant 2.37 ˘ 0.30a 1.36 ˘ 0.14b 0.14 ˘ 0.04b 0.15 ˘ 0.02b 0.92 ˘ 0.10b 1.22 ˘ 0.15b
Spike 2.91 ˘ 0.69b 1.47 ˘ 0.06b 0.13 ˘ 0.02b 0.21 ˘ 0.02c 0.95 ˘ 0.04b 1.30 ˘ 0.05b
p-Value 0.036 0.003 0.050 0.001 0.001 0.001
Values are expressed as the mean ˘ SD of 6 cages per group; a,b,c Values with different superscript letters in
each column differ significantly (p < 0.05); n.d = not detected.
Supplementation with n-3 LC-PUFA diets (both Constant and Spike treatments) led to a significant
increase (p < 0.005) in whole body EPA + DPA + DHAconcentrations compared with Control treatment
and the baseline data, by a factor of 50% increase, over the six weeks of the experiment (data not shown).
In terms of tissue concentrations, no significant differences were observed in EPA and DHA
concentration between these two feeding strategies in any of these four tissues. In contrast, rats on
the Spike treatment had significantly higher concentrations of DPA than those on the Constant treatment
in liver and muscle tissue, but not in heart or adipose tissue (Table 6).
Although EPA was the main n-3 LC-PUFA in the Constant and Spike diets, DHA was the predominant
n-3 LC-PUFA in all tissues analysed except perirenal fat. DPA was the next most deposited n-3
LC-PUFA in tissues, except the in liver, where EPA levels were significantly higher than DPA levels.
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3.6. EPA, DPA and DHA—Mass Balance
Intake and excretion: The Constant treatment provided significantly more EPA, DPA and DHA to
rats compared with the Spike treatment over the duration of the experiment, as noted earlier. Rats under
the Constant treatment excreted significantly more DPA (p < 0.001) and less EPA (p < 0.001) and DHA
(p < 0.001) compared with those in the Spike treatment. In addition, n-6 PUFAintake and excretion were
higher in rats in the Constant compared with the Spike treatment.
Accumulation: The total n-3 LC-PUFA content in whole body in both n-3 enriched treatments over
the 6 weeks of the experiment was significantly higher compared with the Control treatment (p < 0.05),
with no effect between the two feeding strategies being observed (Table 7).
Appearance/disappearance: There was a net disappearance of all n-3 LC-PUFA over the duration
of the experiment (intake greater than accumulation) in both Spike and Constant treatments; with the
exception of the Control treatment where a small net appearance was observed, due to formation from
the dietary 18:3n-3 (Table 7). A statistically significant difference in the net disappearance of all n-3
LC-PUFA were observed as a result of dietary treatment, with values for the Constant treatment being
higher than for the Spike treatment (p < 0.05).
Table 7. Selected fatty acids and fatty acid classes balance (mg/animal) in rats fed under the
different dietary treatments.
PUFA n-6 PUFA n-3 EPA DPA DHA
EPA + DPA
+DHA
Total Intake (mg/Animal)
Control 12812 ˘ 0 a 807 ˘ 0 a n.d n.d n.d n.d
Constant 14685 ˘ 84 c 4256 ˘ 24 c 1662 ˘ 10 b 237 ˘ 1 b 1104 ˘ 6 b 3003 ˘ 17 b
Spike 13115 ˘ 9 b 3161 ˘ 10 b 1208 ˘ 5 a 145 ˘ 1 a 779 ˘ 3 a 2132 ˘ 9 a
p-Value 0.001 0.001 0.001 0.001 0.001 0.001
Excretion (mg/Animal)
Control 84 ˘ 0 a 4 ˘ 0 a n.d n.d n.d n.d
Constant 64 ˘ 0 b 46 ˘ 0 c 10 ˘ 0 a 8 ˘ 0 b 13 ˘ 0 a 31 ˘ 0 a
Spike 84 ˘ 0 a 45 ˘ 0 b 12 ˘ 0 b 5 ˘ 0 a 14 ˘ 0 b 31 ˘ 0 b
p-Value 0.001 0.001 0.001 0.001 0.001 0.001
Net Intake (mg/Animal)
Control 12728 ˘ 0 a 807 ˘ 0 a n.d n.d n.d n.d
Constant 14621 ˘ 84 c 4210 ˘ 24 c 1652 ˘ 9 b 230 ˘ 1 b 1090 ˘ 6 b 2972 ˘ 17 b
Spike 13031 ˘ 9 b 3117 ˘ 10 b 1196 ˘ 5 a 140 ˘ 1 a 764 ˘ 3 a 2101 ˘ 9 a
p-Value 0.001 0.001 0.001 0.001 0.001 0.001
Initial Body Content (mg/Animal)
Control 1331 ˘ 79 a 167 ˘ 10 a 4 ˘ 0 a 18 ˘ 1 a 44 ˘ 3 a 66 ˘ 4 a
Constant 1292 ˘ 107 a 162 ˘ 13 a 3 ˘ 0 a 18 ˘ 1 a 43 ˘ 4 a 64 ˘ 5 a
Spike 1274 ˘ 75 a 160 ˘ 9 a 3 ˘ 0 a 18 ˘ 1 a 42 ˘ 3 a 63 ˘ 4 a
p-Value 0.236 0.127 0.118 0.090 0.417 0.236
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Table 7. Cont.
PUFA n-6 PUFA n-3 EPA DPA DHA
EPA + DPA
+DHA
Final Body Content (mg/Animal)
Control 5183 ˘ 1214 a 386 ˘ 108 a 3 ˘ 3 a 28 ˘ 9 a 144 ˘ 67 a 175 ˘ 76 a
Constant 4450 ˘ 384a 723 ˘ 28 b 66 ˘ 25 b 89 ˘ 30 b 360 ˘ 27 b 616 ˘ 36 b
Spike 4930 ˘ 1042 a 801 ˘ 204 b 67 ˘ 15 b 100 ˘ 21 b 416 ˘ 133 b 582 ˘ 168
b
p-Value 0.346 0.001 0.001 0.001 0.001 0.001
Accumulation (mg/Animal)
Control 3852 ˘ 1285 a 219 ˘ 117 a n.d 9.5 ˘ 10 a 100.2 ˘ 69
a
109 ˘ 80 a
Constant 3158 ˘ 227 a 561 ˘ 26 b 63 ˘ 9 a 71 ˘ 9 b 317 ˘ 28 b 452 ˘ 38 b
Spike 3656 ˘ 1045 a 641 ˘ 204 b 63 ˘ 15 a 82 ˘ 21 b 373 ˘ 133 b 519 ˘ 168
b
p-Value 0.476 0.001 0.001 0.001 0.001 0.001
Appearance/Disappearance (mg/Animal)
Control
´8876 ˘ 1285
a
´584 ˘ 117 a 0.3 ˘ 3 a 10 ˘ 10 a 100 ˘ 69 a 109 ˘ 80 a
Constant
´11463 ˘ 441
a
´3649 ˘ 34 c ´1589 ˘ 13
c
´158 ˘ 9 c ´772 ˘ 23
c
´2520 ˘
30 c
Spike
´9375 ˘ 1043
a
´2475 ˘ 198
b
´1133 ˘ 13
b
´58 ˘ 21 b ´391 ˘ 131
b
´1582 ˘
162 b
p-Value 0.871 0.001 0.001 0.001 0.001 0.001
Values are expressed as the mean˘ SD of 6 cages per group; a,b,c Values with different superscript letters differ
significantly in each column (p < 0.05); n.d = not detected; PUFA (polyunsaturated fatty acid) n-6: 18:2n-6,
20:2n-6, 22:2n-6, 18:3n-6, 20:3n-6, 20:4n-6, 22:4n-6, 24:4n-6, 24:5n-6, 22:5n-6; PUFA n-3: 18:3n-3, 20:3n-3,
22, 3n-3, 18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3, 24:5n-3, 24:6n-3, 22:6n-3.
3.7. EPA, DPA and DHA Apparentin Vivo Metabolism
The Whole Body Fatty Acid Balance Method allowed the calculation of apparent in vivo fatty acid
metabolism (excretion, β-oxidation, bioconversion and deposition) as shown in Table 8. The two most
important pathways identified for the n-3 LC-PUFA in this study were β-oxidation and deposition, which
together accounted for more than 98% of the apparent in vivo metabolism (Table 8).
Based on calculation, the main fate of EPA, DPA and DHA in both n-3 LC-PUFA supplemented
treatments was β-oxidation, except for DPA in rats fed the Spike treatment where deposition was
observed as the main fate. β-oxidation was approximately 95% for EPA, while for DPA and DHA it
ranged between 40% to 70%. There was a significant effect of the dietary treatment on the β-oxidation
for EPA, DPA and DHA, which was higher for rats fed the Constant compared with Spike treatment.
Apart from β-oxidation, deposition was the next main fate of the EPA and DHA in both treatments
and DPA in the Constant treatment. In the case of EPA, deposition amounted to less than 6% of the total
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metabolic activity, whereas in the case of DPA and DHA, deposition accounted for between 30% to 56%
and 28% to 48%, respectively, depending on treatment (Table 8). The whole body deposition of all n-3
LC-PUFA was significantly higher (p < 0.05) in rats fed the Spike treatment compared with those fed
the Constant treatment.
For EPA and DHA there were very similar trends between Spike and Constant treatments (for both
treatments: β-oxidation > deposition > excretion); however, this was not the case for DPA since for
the Constant treatment β-oxidation > deposition > excretion, while for the Spike treatment deposition
> β-oxidation > excretion. DPA was likely not further bio-converted to other n-3 LC-PUFA (namely
24:5n-3, 24:6n-3 or DHA) in any treatment. In the control group, 18:3n-3 was bioconverted at a
significantly higher rate compared with the other two treatments.
The n-6 fatty acid β-oxidation, bioconversion and deposition were similar between all three dietary
treatments. However, the n-6 fatty acid excretion was significantly higher (p < 0.001) in the Spike
compared with the Constant treatment. In the Constant and Spike treatments mostly 18:3n-6 and 20:4n-6
were bioconverted, 20:3n-6 was bioconverted only in the Spike treatment. In the Constant treatment,
mostly 18:2n-6 and 20:4n-6 were deposited while in the Spike treatment, more n-6 fatty acids (18:2n-6,
20:4n-6, 22:4n-6, 22:5n-6) were deposited in the rat’s whole body (data not shown).
Table 8. Metabolic fate of fatty acid (% of the intake) in rats under the three
dietary treatments.
PUFA n-6 PUFA n-3 EPA DPA DHA EPA + DPA + DHA
Excreted (% of Intake)
Control 0.65 ˘ 0.00 c 0.52 ˘ 0.00 a n.d n.d n.d n.d
Constant 0.43 ˘ 0.00 a 1.07 ˘ 0.00 b 0.57 ˘ 0.00 a 3.18 ˘ 1.01 a 1.23 ˘ 0.50 a 1.00 ˘ 0.00 a
Spike 0.62 ˘ 0.00 b 1.40 ˘ 0.00 c 1.02 ˘ 0.00 b 3.52 ˘ 0.00 b 1.84 ˘ 0.00 b 1.44 ˘ 0.00 b
p-Value 0.001 0.001 0.001 0.001 0.001 0.001
β-Oxidised (% of Intake)
Control 69.78 ˘ 9.75 a 74.81 ˘ 12.84 a n.d n.d n.d n.d
Constant 78.23 ˘ 2.74 a 86.30 ˘ 0.74 a 95.66 ˘ 0.57 b 66.61 ˘ 3.62 b 69.98 ˘ 2.43 b 84.44 ˘ 1.20 b
Spike 71.80 ˘ 7.83 a 79.29 ˘ 6.11 a 93.78 ˘ 1.24 a 40.00 ˘ 14.60 a 50.21 ˘ 17.01 a 75.14 ˘ 7.49 a
p-Value 0.096 0.081 0.012 0.008 0.037 0.001
Bio-Converted (% of Intake)
Control 4.90 ˘ 2.81 b 15.72 ˘ 10.10 b n.d n.d n.d n.d
Constant 1.56 ˘ 0.08 a 0.16 ˘ 0.02 a n.d n.d n.d n.d
Spike 3.07 ˘ 1.60 a,b 0.05 ˘ 0.08 a n.d n.d n.d n.d
p-Value 0.026 0.001 - - - -
Deposited (% of Intake)
Control 24.67 ˘ 7.05 a 8.95 ˘ 3.28 a n.d n.d n.d n.d
Constant 19.78 ˘ 2.70 a 12.47 ˘ 0.75 a 3.76 ˘ 0.57 a 30.21 ˘ 3.87 a 28.79 ˘ 2.43 a 14.51 ˘ 1.21 a
Spike 24.51 ˘ 6.32 a 19.26 ˘ 6.04 b 5.24 ˘ 1.24 b 56.50 ˘ 14.60 b 47.9 ˘ 17.0 b 23.42 ˘ 7.49 a
p-Value 0.269 0.002 0.033 0.008 0.042 0.034
Values are expressed as the mean˘ SD of 6 cages per group. a,b,c Values with different superscript letters differ
significantly in each column (p < 0.05); n.d = not detected; PUFA (polyunsaturated fatty acid) n-6: 18:2n-6,
20:2n-6, 22:2n-6, 18:3n-6, 20:3n-6, 20:4n-6, 22:4n-6, 24:4n-6, 24:5n-6, 22:5n-6; PUFA n-3: 18:3n-3, 20:3n-3,
22:3n-3, 18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3, 24:5n-3, 24:6n-3, 22:6n-3.
The apparent in vivo enzyme activities (expressed as mmol of product per g of body weight per day)
are reported in Table 9. The apparent total elongase activity and desaturase activities (∆-5 Desaturase
and ∆-6 Desaturase) were similar in rats under the Constant and the Spike treatment. The apparent ∆-9
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Desaturase enzyme activity was higher in rats under the Spike treatment compared with those on the
Constant treatment.
Table 9. Apparent in vivo enzyme activities in rats fed the three dietary treatments.
ź Elongase
ź ∆-9
Desaturase
ź ∆-6
Desaturase
∆-6
Desaturase
for n-6
∆-6
Desaturase
for n-3
ź ∆-5
Desaturase
∆-5
Desaturase
for n-6
∆-5
Desaturase
for n-3
Control 629 ˘ 335 b 1305 ˘ 245 c 298 ˘ 192 b 228 ˘ 142 b 69 ˘ 49 227 ˘ 147 b 195 ˘122 b 31 ˘ 24
Constant 97 ˘ 15 a 375 ˘ 134 a 48 ˘ 4 a 48 ˘ 4 a n.d 56 ˘ 5 a 56 ˘ 5 a n.d
Spike 219 ˘ 146 a 722 ˘ 240 b 114 ˘ 67 a,b 114 ˘ 67 a,b n.d 108 ˘ 61 a,b 108 ˘61 a,b n.d
p-Value 0.001 0.001 0.006 0.012 - 0.017 0.025 -
Values are expressed in mmol/g/day as the mean ˘ SD of 6 cages per group; a,b,c Values with different
superscript superscript letters differ significantly in each column (p < 0.05); n.d = not detected. The Greek
letter capital sigma (Σ) indicates summation.
4. Discussion
The present study sought to examine the whole body bioavailability and efficiency (as n-3 LC-PUFA
metabolic fate) of the same overall dose of n-3 LC-PUFA, provided from the same source (fish oil), at
the same overall weekly dose, but at different frequencies: dailyvs. weekly. It was found that the growth
of the animals was not different between treatments and no mortalities were recorded amongst the three
experimental treatments (Constant, Spike and Control). There were significant but small differences in
the excretion of the n-3 LC-PUFA between the Spike and Constant treatment groups, which are unlikely
to be nutritionally relevant.
The results obtained by simply comparing tissue FA concentrations (mg/g tissue) were interesting,
but they are admittedly of limited value towards achieving a better understanding of n-3 LC-PUFA
“bioavailability”. While the dietary intake of n-3 LC-PUFA provided by the two diets were similar, but
not identical, there were some differences between treatments that might be independent of the difference
in dietary intake. For example, the DPA concentration in liver and muscle was significantly greater in the
Spike treatment than in the Constant treatment, despite the dietary DPA intake being significantly greater
for the Constant treatment. This has no obvious explanation, but reveals that metabolic processing of
dietary n-3 LC-PUFA is more complex than simply looking at dietary intake values or tissue levels.
A much greater and more accurate understanding of the actual metabolic fate of n-3 LC-PUFA
provided by different oils can be achieved by observing the results of the Whole Body Fatty Acid Balance
Method, which takes into account, and thus balances out, any differences in dietary intake.
This data showed that the major metabolic fate of the n-3 LC-PUFA (EPA + DPA + DHA) was towards
catabolism (β-oxidation) accounting for over 70% of total dietary intake, whereas deposition accounted
less than 25% of total dietary intake. It was found that significantly more n-3 LC-PUFA were β-oxidised
when originating from the Constant treatment (84% of dose), compared with the Spike treatment (75% of
dose). Conversely, it was found that significantly more n-3 LC-PUFA were deposited when originating
from the Spike treatment (23% of dose), than from the Constant treatment (15% of dose). This result
suggests that the n-3 LC-PUFA provided by the Spike treatment were more deposited (bioavailable),
compared with those provided by the Constant treatment.
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The differences in β-oxidation and deposition were not the same for each of EPA, DPA and DHA
for either the Spike or Constant treatment. That is, EPA was more extensively β-oxidised than DPA
and DHA on both treatments, but the differences between the 20 carbonand the 22 carbon PUFA were
accentuated in the Spike treatment. In the case of β-oxidation, the Constant/Spike ratios were 1.7
for DPA and 1.4 for DHA, but only 1.0 for EPA. In terms of deposition, the Constant/Spike ratios
were 0.5 for DPA, 0.6 for DHA, and 0.7 for EPA. This suggests that EPA is preferentially directed
towards β-oxidation almost independent of whether the EPA is provided daily or once per week. This
is consistent with data showing high affinity of EPA to catabolism (β-oxidation) in animal models [23].
It has been reported using Wistar rats that EPA-CoA was a good substrate for mitochondrial carnitine
acyl-transferase-I and DHA was a poor substrate for both mitochondrial and peroxisomal β-oxidation,
which could explain the high rate of β-oxidation for EPA [23].
In contrast to EPA, it would appear that DHA and DPA are somewhat spared from β-oxidation when
consumed, as observed previously [24] but especially when a large dose of dietary n-3 LC-PUFA is
provided weekly. This is consistent with the finding of Kaur et al. [24] in rodents who showed, using
radiolabelled EPA, DPA and DHA in rats, that six hours after dosing 19% of the EPA was β-oxidized
and expired as CO2 compared with 5% in case of DPA and 7% of DHA. However, these data do not shed
any light on why providing a bolus dose of n-3 LC-PUFA leads to a greater partitioning of DPA and
DHA towards deposition. With the Spike treatment, it is therefore possible to speculate that this “flood”
of n-3 LC-PUFA could have saturated the capacity of the mitochondria to β-oxidise any extra DPA and
DHA, resulting in a greater retention and deposition of these fatty acids in tissues.
To our knowledge, this is the first study to compare the whole body bioavailability of n-3 LC-PUFA
in rats fed a constant daily dosevs. a larger and less frequent dose of the same dietary source of n-3
LC-PUFA. From the two available human studies comparing a weekly dose of n-3 LC-PUFA with daily
dose, only one study used the same source of n-3 LC-PUFA (capsules not fish meal) [12]. Both studies
used blood levels (plasma, platelets or mononuclear cells) as a proxy for bioavailability. The limitations
of these studies include a failure to provide the dose adjusted on a body weight basis, the failure to
measure excretion and the failure to measure the EPA and DHA levels in the red blood cells (which
are widely regarded as the best measure of EPA + DHA tissue status). Furthermore, because of the
known high level of variability in the response of subjects to the same dose of fish oil (as noted by
Kohler et al. [25]), these studies have limitations because the data was not adjusted for by gender, body
weight or exercise level [26]. In the present rat study, rats were fed to fixed predetermined ration, which
was adjusted weekly relative to body weight, for 6 weeks which helped to reduce the variability of
the results achieved, increased the statistical power of the test (greater than 80% for the vast majority
of data recorded), and ultimately contributed to obtaining more robust, substantiated and more easily
interpretable findings.
The possible difference in bioavailability of n-3 LC-PUFA when provided in different edible sources
has received some research attention. Specifically, the blood levels of n-3 LC-PUFA derived from daily
fish oil capsules compared with either adaily fish meal or daily fish oil enriched food have been reported
in a few studies [27–30].
In the current study, the Constant and the Spike treatment showed lower levels of apparent in vivo
enzyme activity for elongase, ∆6 and ∆5 desaturase compared with the Control treatment. Lower ∆6
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desaturase activity with fish oil feeding has been previously reported [31]; however, there is no data
looking at a weeklyvs. daily dose to compare with. These desaturases and elongases are required
for the biosynthesis of LC-PUFA and their inter-conversion. High availability of these fatty acids in
Constant and the Spike treatment can act via a negative feedback control mechanism and reduce the
gene transcription rate and the actual activity of the desaturase and elongase enzymes in these treatments,
possibly via sterol regulatory element binding protein (SREBP-1c) [32,33]. On the other hand, the lack
of n-3 LC-PUFA intake in the diet of the Control rats has likely increased their elongase and desaturase
enzyme activities in order to increase endogenous n-3 LC-PUFA synthesis. Dietary n-3 LC-PUFA
deprivation has previously been shown to upregulate liver mRNA levels of ∆6 and ∆5 desaturases as
well as activities of ∆6 and ∆5 desaturases [34,35].
Overall, there were no significant differences in the assessed enzyme activities between the Spike
and Constant treatments, with the exception of ∆9 desaturase (required for the biosynthesis of
monounsaturated fatty acids), which was significantly higher in the Spike treatment.
Admittedly, one of the limitations of the present study includes being an animal study in male rats.
Nevertheless, these preliminary, novel and highly interesting findings warrant further investigations, and
in particular the need to be substantiated by conducting appropriate trials in humans. It is worth noting
that the dose of n-3 LC-PUFA used in the Constant treatment equates to 1012 mg/day for a 70 kg
human [36], which is in the range of human recommendations for these fatty acids. Another limitation,
as previously mentioned, was that the slightly different total amounts of n-3 LC-PUFA administered
by the two n-3 LC-PUFA enriched dietary treatments used in this study. However, these differences
are relatively minimal, and unlikely to be responsible of any major modification in the overall n-3
LC-PUFA metabolism, and have been accounted for in the Whole Body Fatty Acid Balance Method.
A third limitation is that these results do not apply to comparative effects of consumption of daily fish oil
capsules vs. a sporadic meal with fish or seafood, since the study investigated the bioavailability of the
same food source of n-3 LC-PUFA; but this was intentional to exclude the possible effect of the matrix
(food source) of the dietary n-3 LC-PUFA.
In conclusion, our data show that there was a significantly greater deposition of the n-3 LC-PUFA
associated with a single large dose of dietary n-3 LC-PUFA compared with the smaller daily doses in rats,
due to less β-oxidation and greater deposition, and not due to differences in excretion (digestibility). The
results from this animal study provide a suitable platform for future human studies aimed at developing
substantiated evidence for advising consumers on the most efficient way to increase their n-3 LC-PUFA
status.These findings suggests that a large dose of n-3 LC-PUFA once per week is more effective
in increasing whole body n-3 LC-PUFA content compared to a smaller dose delivered daily. This
observation, if validated in humans, could have remarkable effects on the possible development of more
effective and sustainable utilisation strategies of these limited and metabolically important nutrients,
currently derived primarily from the dwindling oceanic fish stocks.
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